Results 271 to 280 of about 281,052 (341)

First‐Line Therapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Retrospective, Multicenter, Real‐World Study

Head &Neck, EarlyView.
ABSTRACT Background In Europe, pembrolizumab with or without chemotherapy is the recommended first‐line treatment for recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC), with a combined positive score (CPS) ≥ 1. In France, the TPExtreme (TPEx) regimen is preferred for CPS < 1.
Alizée Simon, Cyril Abdeddaim, DucTrung Nguyen, Patrice Gallet, Didier Peiffert, Aurélien Lambert, Lionnel Geoffrois   +6 more
wiley   +1 more source

Submicron-sized superantigen biomimetic liposomes: enhanced lung accumulation and synergistic chemoimmunotherapy. [PDF]

Acta Pharm Sin B
Jia F, Peng S, Wang W, Pan X.
europepmc   +1 more source

Therapeutic targeting of chromatin alterations in leukemia and solid tumors

International Journal of Cancer, EarlyView.
Abstract Alterations in chromatin conformation and post‐translational modification of histones have become increasingly recognized as critical drivers of cancer development, progression, and therapy resistance. Recent advances in drug development have led to the establishment of several highly selective small molecule inhibitors, several of which are ...
Florian Perner, Tobias Berg, Daniel Sasca, Sophie‐Luise Mersiowsky, Jayant Y. Gadrey, Johanna Thomas, Michael W. M. Kühn, Michael Lübbert   +7 more
wiley   +1 more source

Complete remission of recurrent uterine angiosarcoma following long-term systemic chemotherapy with paclitaxel and carboplatin: A case report. [PDF]

Oncol Lett
Inoue Y, Hashiguchi Y, Kuwae Y, Yamamoto A, Koyama M, Yamamoto K, Tamura K.   +6 more
europepmc   +1 more source

Blood‐based biomarkers in soft tissue sarcoma: Implications for immune checkpoint inhibitor therapy

International Journal of Cancer, EarlyView.
Abstract Soft tissue sarcoma (STS) is a rare and heterogeneous cancer, comprising approximately 1% of all adult cancers and 7%–15% of all childhood cancers. In the advanced stages, chemotherapy remains the standard‐of‐care, but efficacy is limited, with a response rate of 15%–30%, and responses are often short‐lived, with median progression‐free ...
Brie‐Anne Mannah, John J. Park, Su Yin Lim   +2 more
wiley   +1 more source

Attention-based multimodal deep learning for interpretable and generalizable prediction of pathological complete response in breast cancer. [PDF]

J Transl Med
Nishizawa T, Maldjian T, Jiao Z, Duong TQ.   +3 more
europepmc   +1 more source

Apoptosis regulators of the Bcl‐2 family play a key role in chemoresistance of cholangiocarcinoma organoids

International Journal of Cancer, EarlyView.
What's New? Poor prognosis in cholangiocarcinoma (CCA) is attributed to late diagnosis and intrinsic chemoresistance. In particular, resistance mechanisms that suppress apoptosis limit the effectiveness of gemcitabine‐based regimens, which remain the standard treatment.
Wunan Mi, Gilles S. van Tienderen, Shaojun Shi, Amy Broeders, Kathryn Monfils, Henk P. Roest, Luc J. W. van der Laan, Monique M. A. Verstegen   +7 more
wiley   +1 more source

Exploring the anticancer potential of green silver Nanoparticles-Paclitaxel nanocarrier on MCF-7 breast Cancer cells: an in vitro approach. [PDF]

Sci Rep
Aboul-Nasr MB, Yasien AA, Mohamed SS, Aboul-Nasr YB, Obiedallah M.   +4 more
europepmc   +1 more source

Phase II clinical trials of cisplatin-then-paclitaxel and paclitaxel-then-cisplatin in patients with previously untreated advanced epithelial ovarian cancer

, 2000
Christopher Poole, Timothy Perren, Andrea Burton, Samuel D. Jordan, A. Jenkins, J. Mould, D. Spooner, David Luesley, Karen K. L. Chan, S. Sturman, Helena Earl   +10 more
openalex   +1 more source

Mass cytometric detection of homologous recombination proficiency in circulating tumor cells to predict chemoresistance of metastatic breast cancer patients

International Journal of Cancer, EarlyView.
What's New? Circulating tumor cells can offer insights into treatment responses and metastatic recurrence, but current analysis methods are limited. Here, the authors tested a newly developed mass cytometry panel comprising biomarkers such as γH2AX and RAD51 in longitudinally monitored metastatic breast cancer patients.
Kathrin Niedermayer, Henning Schäffler, Georgios Vlachos, Sara Greco, Kerstin Pfister, Barbara Volz, Leonie Ott, Hans Neubauer, Bernhard Polzer, André Koch, Sabine Riethdorf, Tanja Fehm, Wolfgang Janni, Thomas W. P. Friedl, Brigitte Rack, Ellen Heitzer, Fabienne Schochter, Lisa Wiesmüller   +17 more
wiley   +1 more source